NIH Clinical Center: Search the Studies

Search the Studies

18 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
001559-C	A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	Recruitment has not started	18-120 Years	NCI	Melanoma
000958-C	Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment	Enrolling by Invitation	18-125 Years	NCI	Melanoma
000354-C	Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma	Participants currently recruited/enrolled	18-125 Years	NCI	Melanoma
000251-C	The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)	Participants currently recruited/enrolled	18-120 Years	NCI	Melanoma
19-C-0010	A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors	Completed Study; data analyses ongoing	18-125 Years	NCI	Melanoma
18-C-0110	Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers	Participants currently recruited/enrolled	18-99 Years	NCI	Melanoma
16-C-0131	A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers	Participants currently recruited/enrolled	18-72 Years	NCI	Melanoma
16-C-0066	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	Completed Study; data analyses ongoing	18-120 Years	NCI	Melanoma
16-C-0027	A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab	Clinical hold/Recruitment or enrollment suspended	18-70 Years	NCI	Melanoma
14-C-0059	A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors	Completed Study; data analyses ongoing	1-35 Years	NCI	Melanoma
14-C-0022	A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm	Completed Study; data analyses ongoing	18-70 Years	NCI	Melanoma
11-C-0123	A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with	No longer recruiting/follow-up only	18-66 Years	NCI	Melanoma
10-C-0166	A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab	Participants currently recruited/enrolled	18-72 Years	NCI	Melanoma
09-C-0161	Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies	Enrolling by Invitation	18-125 Years	NCI	Melanoma
03-C-0277	Cell Harvest and Preparation for Surgery Branch Treatment Protocols	Enrolling by Invitation	18-125 Years	NCI	Melanoma
02-C-0211	Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma	Participants currently recruited/enrolled	0-125 Years	NCI	Melanoma
01-C-0129	Eligibility Screening for the NIH Intramural Research Program Clinical Protocols	Enrolling by Invitation	0-125 Years	NCI	Melanoma
99-C-0128	Evaluation for NCI Surgery Branch Clinical Research Protocols	Participants currently recruited/enrolled	18-125 Years	NCI	Melanoma